Study wrapper · #944
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Goetz IA, Kanu C, Hoover A, et al. Obesity pillars. 2025.
DOI: 10.1016/j.obpill.2025.100220PubMed: 41216380
Editor's note
This qualitative exit-interview study captures patient-reported experiences from a Phase 2 retatrutide trial rather than clinical efficacy outcomes. Participants described reduced appetite, portion changes, and improved well-being, though a few reported social limitations or frustration. Useful for the lived-experience angle, with the caveat that self-reported perceptions from a small sample cannot establish efficacy.
Plain-language abstract
In a qualitative study, 40 participants exiting a Phase 2 retatrutide trial described early changes in eating behavior, improved physical and emotional well-being, and progress toward weight-loss goals, with some reporting side effects or unmet expectations.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026